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PreviewsFluid retention mediated by renal PPARγ
Thiazolidinediones are activators of the nuclear receptor PPARγ with proven efficacy on glucose homeostasis. However,
treatment with these drugs often results in fluid retention and edema. Recent studies establish a role for PPARγ in renal
sodium reabsorption, providing a mechanism for the plasma volume expansion induced by these drugs.Thiazolidinediones (TZDs), or glitazones, r
are a class of oral antidiabetic drugs that l
cact as insulin sensitizers (Yki-Järvinen,
2004). It is generally accepted that TZDs c
wexert their effects on glucose homeosta-
sis via activation of the nuclear receptor a
PPARγ, a key regulator of adipogenesis.
In addition to being highly expressed in s
oadipose tissue, which is thought to ac-
count for the molecular basis of the insu- m
mlin-sensitizing activities of TZDs, PPARγ is
also expressed in other tissues, such as h
nthe vasculature, where it impacts on the
inflammatory response and cholesterol d
Bhomeostasis (Marx et al., 2004). These
pleiotropic actions of PPARγ have raised p
aexpectations that TZDs may also improve
cardiovascular function, which would be e
nbeneficial to type 2 diabetes patients,
who are at increased risk of life-threaten- i
aing cardiovascular disease (CVD). Several
clinical outcome trials testing the cardio- c
aprotective actions of TZDs are currently
underway (PROactive, DREAM, RECORD), b
cthe results of which should soon become
available. Despite its positive effect, TZD
ptreatment is, however, generally accom-
panied by a modest but significant in- o
pcrease in body mass due to both an in-
crease in adipose tissue and body fluid t
qexpansion, often associated with edema
(w4%–6% of treated patients, a percen- s
Ptage that increases upon combination treat-
ment with insulin). Two recent studies c
g(Zhang et al., 2005; Guan et al., 2005) now
address the mechanism of fluid expan- a
lsion following TZD treatment and impli-
cate PPARg in renal sodium reabsorption. u
wIt is fairly well understood that an in-
crease in adipose tissue mass is inherent t
tto the activation of PPARγ and ensuing
adipocyte differentiation, as well as to the p
wanabolic effects associated with insulin
sensitization, an effect often observed upon t
linsulin therapy. By contrast, the mecha-
nisms of fluid expansion and edema a
dupon TZD treatment have been, until
now, less well understood, and both in-
fcreases in peripheral vascular permeabil-
ity and direct renal effects have been h
tincriminated. Although the TZD-associ-
ated edema is mainly restricted to the pe- TCELL METABOLISM : AUGUST 2005 · VOL. 2 · Ciphery and does not impair left ventricu- a
far function, these classes of drugs are
ontraindicated in patients with NYHA m
class III and IV congestive heart failure, in
hom further burden on the heart is to be z
avoided (Nesto et al., 2004).
Recently, a number of reports have f
eought to address the effects of TZDs
n kidney function in preclinical rodent t
dodels. Chen et al. (2005), using a phar-
acological approach in rats with the T
Mighly potent and selective PPARγ ago-
ist farglitazar, showed increased so- b
aium reabsorption in the distal nephron.
ased on the decrease in the plasma p
cotassium/sodium ratio as well as plasma
ldosterone concentrations and altered a
fxpression of genes involved in distal
ephron sodium and water reabsorption,
bncluding the Na-K-ATPaseα, SGK1, and
quaporin2 (AQP2), these authors con- r
tluded that farglitazar increased sodium
bsorption in the distal nephron, proba- m
rly by stimulating the epithelial sodium
hannel (ENaC) and Na-K-ATPase system. t
nHowever, although PPARγ is ex-
ressed in the medullary collecting duct s
hf the distal nephron, these data did not
rovide evidence for its involvement in o
the TZD-induced fluid retention. This
uestion, which is particularly relevant m
tince TZDs have been shown to exert
PARγ-independent effects in various d
eell types and tissues, has been ele-
antly addressed by Zhang et al. (2005) t
cnd Guan et al. (2005), who created col-
ecting duct-specific PPARγ-deficient mice 2
ssing the Cre/Lox strategy. Both studies
ere remarkably consistent, showing that d
Shese PPARγ-deficient mice are resistant
o TZD-induced body weight gain and 2
rlasma volume expansion associated
ith alterations in renal sodium excre-
lion. Moreover, TZD stimulation of ami-
oride-sensitive sodium transport was r
cbolished in primary cultures of PPARγ-
eficient collecting duct cells. p
sUnfortunately, the molecular targets
or PPARγ in the collecting duct cells n
tave not been clearly established. Al-
hough Guan et al. (2005) reported that e
sZDs induce ENaCγ expression as wellOPYRIGHT © 2005 ELSEVIER INC.s PPARγ binding to its intron, a detailed
unctional analysis of the ENaCγ pro-
oter has not yet been performed. In
ontrast, in vivo treatment with farglita-
ar did not result in major changes in
ny of the ENaC subunits, even though
luid retention was clearly observed (Chen
t al., 2005). In addition, these latter au-
hors reported that ameloride treatment
id not prevent but rather enhanced
ZD-induced blood volume expansion.
oreover, not only ameloride-sensitive,
ut also ameloride-insensitive transport
ppeared affected by TZD treatment in
rimary collecting duct cells. Further elu-
idation of the molecular mechanisms of
ction of PPARγ in these cells is there-
ore necessary.
Although these observations establish
eyond any doubt a role for PPARγ in
enal sodium transport and as a media-
or of TZD effects, several questions re-
ain. First of all, will these findings in
odents be relevant to the clinical situa-
ion in humans? Such extrapolation can-
ot be made by default, since notorious
pecies differences in PPARγ function
ave been reported, a striking example
f which is the PPARγ-dependent induc-
ion of hepatic steatosis in TZD-treated
ice (Gavrilova et al., 2003) in contrast
o the reduction in liver fat seen in type 2
iabetic patients (Bajaj et al., 2003; May-
rson et al., 2002). TZDs may also act on
he proximal tubules in the kidney to in-
rease sodium reabsorption (Zanchi et al.,
004), and PPARγ agonists have been
hown to increase cell surface ENaCα in-
irectly via transcriptional induction of
GK1 in cultured human cells (Hong et al.,
003). These discrepancies therefore war-
ant further mechanistic studies.
Is this the entire story? It appears un-
ikely. Indeed, in the animal experiments
eported by Zhang et al. (2005), the in-
reased blood volume and decreased
lasma aldosterone and hematocrit were
ignificantly blunted after TZD treatment,
ot entirely abolished. Moreover, if TZD
reatment induces body fluid expansion
xclusively by promoting sodium reab-
orption, one would anticipate an increase77
P R E V I E Win blood pressure rather than the de- o
ocrease reported in several clinical studies.
Thus, it appears plausible that vascular v
effects, which are a prerequisite for c
edema formation, may contribute to the c
overall effects of TZDs. Such effects (
may be due to interference with the an- e
giotensinII/AT1R or endothelin-1 path- t
ways, as well as an effect on the release i
Tof NO, all of which are regulated by
PPARγ (Marx et al., 2004). a
Which perspectives do these new and a
exciting results offer? First, since a direct p
role for PPARγ in kidney function has now
cbeen identified, the identification of its
target genes will allow the initiation of ge- k
netic studies that may help identify individ- b
uals likely to develop edema. Similarly, if e
wpolymorphisms in the ENaC genes are as-
sociated with edema, patients at risk could c
abe screened before initiating TZD therapy.
Such genetic approaches should also m
provide evidence for the effects of TZDs f
in the kidney in humans. Second, the P
tidentification of the site of action of
PPARγ in the kidney opens perspectives c
for targeted treatment with an appropri- i
ate diuretic in specific patients. Indeed, e
pGuan et al. (2005) proposed that treat-
ment with ameloride, a selective inhibitor i
of collecting duct salt absorption acting s
mthrough ENaC, could be appropriate and
provided experimental evidence for this.
Further clinical studies should reveal
B
U
whether diuretics acting on the distal neph-
ron, such as ameloride or spironolactone,
Dan inhibitor of aldosterone, will be effective
Iin the treatment of TZD-induced edema in
patients. Although by no means definitive,
Uthese data support the notion that TZDs
Lact on the distal nephron. Third, further
Fidentification of the molecular mechanism78Sf PPARγ in the renal collecting duct cells
pens new perspectives for future drug de-
B
elopment. Indeed, significant efforts are H
urrently being undertaken to identify and s
haracterize selective PPARγ modulators (
SPPARMs) devoid of the undesirable side
C
ffects of the currently used TZDs. Al- B
hough not unequivocally demonstrated, t
Pt is likely that the fluid retention effects of
ZDs require higher doses of full agonists G
nd thus partial PPARγ agonism may be K
Znother way to create an improved thera-
Peutic window.
nIn conclusion, these recent reports
learly demonstrate a role for PPARγ in the H
Bidney as a mechanism contributing to the
Olood volume expansion and possibly
Fdema induced by TZDs. The information
ill undoubtedly contribute to the identifi- M
(ation of patients at risk, their better man-
gement, and, possibly, the design of new, M
ore selective drugs devoid of side ef- V
zects. Depending on the outcome of the
(ROactive study, which will be the first of
hese landmark trials to report at the up- N
oming EASD meeting in September 2005, G
Dt can be expected that TZD use will be
Dxtended to prevent CVD in type 2 diabetic
atients. Since edema is the principal clin- G
Jcal limitation for this class of drugs, further
Ctudies on the mechanisms involved are of
Bajor importance.
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